Clinical Trials Browser

Has results × enzalutamide × 90 days × Clear all

NCT01885949 2026-05-20

Tivozanib + Enzalutamide in Adv Prostate Cancer

Phase 2 Terminated

5 enrolled 8 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT03437941 2026-05-15

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Terminated

39 enrolled 43 charts

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT05730712 2026-05-15

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

7 enrolled 10 charts

Prostatic Neoplasms

NCT02312557 2026-05-14

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Phase 2 Active not recruiting

58 enrolled 13 charts

Prostatic Neoplasms

NCT03644303 2026-05-14

TRAP

Phase NA Completed

86 enrolled 27 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT02689427 2026-05-12

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

Phase 2 Completed

24 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04262154 2026-05-11

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Phase 2 Active not recruiting

28 enrolled 9 charts

Prostatic Neoplasms

NCT02319837 2026-05-07

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Phase 3 Active not recruiting

1,068 enrolled 20 charts 1 FDA

Prostatic Neoplasms

NCT04191096 2026-04-29

KEYNOTE-991

Phase 3 Completed

1,251 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT02555189 2026-04-22

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Phase 1/2 Terminated

52 enrolled 31 charts

Prostatic Neoplasms

NCT03395197 2026-04-22

TALAPRO-2

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Phase 4 Active not recruiting

43 enrolled 16 charts

Metastatic Castration-resistant Prostate Cancer

NCT04076059 2026-04-17

China ARCHES

Phase 3 Active not recruiting

180 enrolled 24 charts

Metastatic Hormone Sensitive Prostate Cancer